gc012f
gracell biotechnologies
['hodgkin', 'gc012f ', 'lymphoma', 'gracell']
gracell biotechnologies presents longer-term results for fastcar-t gc012f in b-cell non-hodgkin s lymphoma at eha2023, highlighting 100% overall response rate #stocksoftheday #stockalert #stocknews #cancer 
Find the most important news and press releases about U.S. publicly-traded companies in real-time and stay ahead of the game!